GYRE · Insider Trading
Gyre Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by GYRE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-04 | Claire Weston | Director | A | +40,000 deriv. | — |
| 2026-08-04 | Maxwell Kirkby | Director | A | +40,000 deriv. | — |
| 2026-06-22 | Weiguo Ye | Chief Operating Officer | MIXED | — | −$60.45K |
| 2026-06-15 | Weiguo Ye | Chief Operating Officer | MIXED | — | −$15.18K |
| 2026-06-11 | Weiguo Ye | Chief Operating Officer | MIXED | — | −$113.20K |
| 2026-06-10 | Ying Luo | Chief Executive Officer | A | +120,000 deriv. | — |
| 2026-06-10 | Joshua Benjamin Bergmann | GC and Corporate Secretary | A | +50,000 deriv. | — |
| 2026-06-08 | Weiguo Ye | Chief Operating Officer | MIXED | — | −$192.33K |
| 2026-05-27 | Weiguo Ye | Chief Operating Officer | MIXED | — | −$40.06K |
| 2026-05-22 | Weiguo Ye | Chief Operating Officer | MIXED | — | −$119.99K |
| 2026-05-20 | Ping Zhang | Director | D | −250,000 deriv. | — |
| 2026-05-20 | Weiguo Ye | Chief Operating Officer | MIXED | — | −$52.43K |
| 2026-05-18 | Weiguo Ye | Chief Operating Officer | MIXED | — | −$173.26K |
| 2026-05-07 | Ying Luo | Chief Executive Officer | Sell | −10,315 | −$82.93K |
| 2026-05-06 | GNI USA, Inc. | 10%+ Owner | J | +2,601,826 deriv. | — |
| 2026-05-06 | Thomas Wilson Eastling | Chief Financial Officer | A | +408,757 deriv. | — |
| 2026-01-09 | Ping Zhang | Director | A | +100,000 deriv. | — |
| 2026-01-09 | Ruoyu Chen | Chief Financial Officer | A | +50,000 deriv. | — |
| 2025-08-26 | Dan Weng | Director | A | +52,000 deriv. | — |
| 2025-08-07 | Ping Zhang | Director | A | +250,000 deriv. | — |
| 2025-06-06 | Renate Parry | Director | A | +26,000 deriv. | — |
| 2025-06-06 | David M. Epstein | Director | A | +26,000 deriv. | — |
| 2025-06-06 | Thomas Wilson Eastling | Director | A | +26,000 deriv. | — |
| 2025-06-06 | Gordon Carmichael | Director | A | +26,000 deriv. | — |
| 2025-06-06 | Rodney L Nussbaum | Director | A | +26,000 deriv. | — |
| 2025-05-29 | Songjiang Ma | President | Sell | −2,558 | −$26.18K |
| 2025-05-28 | Ping Zhang | Director | A | +250,000 deriv. | — |
| 2025-05-27 | Songjiang Ma | President | Sell | −2,182 | −$23.80K |
| 2025-05-22 | Songjiang Ma | President | Sell | −4,000 | −$44.16K |
| 2025-05-20 | Songjiang Ma | President | Sell | −4,000 | −$44.84K |
| 2025-05-16 | Songjiang Ma | President | Sell | −2,020 | −$21.59K |
| 2025-05-14 | Songjiang Ma | President | Sell | −4,000 | −$43.86K |
| 2025-05-14 | Weiguo Ye | Chief Operating Officer | M | +50,000 | +$37.50K |
| 2025-04-25 | Weiguo Ye | Chief Operating Officer | M | +650,000 | +$487.50K |
| 2025-04-18 | Thomas Wilson Eastling | Director | M | +15,000 | +$103.95K |
| 2025-03-25 | Songjiang Ma | President | Sell | −174 | −$1.74K |
| 2025-03-21 | Songjiang Ma | President | Sell | −4,000 | −$40.44K |
| 2025-03-19 | Songjiang Ma | President | Sell | −2,242 | −$26.66K |
| 2025-03-17 | Songjiang Ma | President | Sell | −4,000 | −$48.22K |
| 2025-03-13 | Songjiang Ma | President | Sell | −4,000 | −$46.28K |
| 2025-03-11 | Weiguo Ye | Chief Operating Officer | A | +300,000 deriv. | — |
| 2025-03-11 | Songjiang Ma | President | Sell | −4,000 | −$40.78K |
| 2025-03-07 | Songjiang Ma | President | Sell | −4,000 | −$43.56K |
| 2025-03-05 | Songjiang Ma | President | Sell | −4,000 | −$44.18K |
| 2025-03-03 | Songjiang Ma | President | Sell | −4,000 | −$45.48K |
| 2025-02-27 | Songjiang Ma | President | Sell | −4,000 | −$46.00K |
| 2025-02-25 | Songjiang Ma | President | Sell | −4,000 | −$45.19K |
| 2025-02-21 | Songjiang Ma | President | Sell | −4,000 | −$49.38K |
| 2025-02-19 | Songjiang Ma | President | Sell | −4,000 | −$48.86K |
| 2025-02-14 | Songjiang Ma | President | Sell | −4,000 | −$46.36K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Songjiang Ma | President | 2,806,642 | $12.04M |
| Ying Luo | Chief Executive Officer | 2,575,362 | $11.05M |
| Weiguo Ye | Chief Operating Officer | 703,000 | $3.02M |
| Thomas Wilson Eastling | Chief Financial Officer | 15,000 | $64.35K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GYRE quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.